Nonselective beta-adrenoblocker carvedilol with vasodilating properties in the therapy of cardiovascular diseases
beta-blockers (BAB) widely used in clinical practice. Large clinical studies have shown that BAB can improve the prognosis in patients with cardiovascular diseases. However, recent years have increasingly raised the issue that BAB reduce the stroke risk in patients with arterial hypertension (AH) less effectively compared with other antihypertensive drugs, and are metabolically unsafe drugs. Carvedilol - nonselective beta1- and beta2- adrenoreceptors blocker with antioxidant action and vasodilating properties due to the additional blockade of alpha1-adrenergic receptors, has proven clinical efficacy in patients with hypertension, ischemic heart disease, congestive heart failure. In addition, large clinical studies of carvedilol safety demonstrated its application is not accompanied by disturbances in lipid and carbohydrate metabolism that creates additional benefits for the use of this drug in clinical practice.

Keywords: alpha1-adrenergic receptors, carvedilol, chronic heart failure, beta-blockers, arterial hypertension